Modality
Multispecific
MOA
CDK2i
Target
AuroraA
Pathway
Hedgehog
PVWM
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
→ Nov 2028
Phase 1Current
NCT03888801
2,041 pts·WM
2022-04→2028-11·Not yet recruiting
2,041 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-072.6y awayPh2 Data· WM
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2028-11-07 · 2.6y away
WM
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03888801 | Phase 1/2 | WM | Not yet recr... | 2041 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |